Evidence map›Paper›PMID 16731270›Full record

ArticleLancet (London, England)2006

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

Alan D Lopez, Colin D Mathers, Majid Ezzati, Dean T Jamison, Christopher J L Murray

11 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Lancet (London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 11 registered trials, which are not on this map. Cited by 1,968 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,968citing papers in PubMed, 5 pooled it
178.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01321255 phase3completedstarted 2012, after this paper: background citation

Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug

Ran2012Enrolled2,118Registered outcomes6Posted comparisons0ConditionsMyocardial InfarctionArmsFDC, Separately drugs, simvastatin, aspirin and ramipril
Open the trial in the graph
NCT05553613 phase3completednot on this mapstarted 2022, after this paper: background citation

Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial

TypeinterventionalSponsorKafrelsheikh UniversityRan2022 to 2024Enrolled900ConditionsIschemic StrokeArmsTicagrelor 90 MG Oral Tablet, Clopidogrel tablet
NCT05874661 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Effect of Focus of Attention on Motor Performance and Learning During a Sit to Stand Task in Individuals Post-stroke

TypeinterventionalSponsorWestern Carolina UniversityRan2023 to 2024Enrolled16ConditionsStroke, AcuteArmsExternal Focus of Attention, Internal Focus of Attention
NCT06058884 phase4completednot on this mapstarted 2022, after this paper: background citation

Predictors of the Unfavourable Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase, a Multi-centre Prospective Study

TypeinterventionalSponsorKafrelsheikh UniversityRan2022 to 2023Enrolled592ConditionsIschemic Stroke, Alteplase Adverse ReactionArmsAlteplase
NCT06120725 phase3completednot on this mapstarted 2021, after this paper: background citation

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial

TypeinterventionalSponsorKafrelsheikh UniversityRan2021 to 2023Enrolled580ConditionsIschemic StrokeArmsTicagrelor 90 MG, Clopidogrel
NCT06163859 nacompletednot on this mapstarted 2024, after this paper: background citation

Female Community Health Volunteers Led Hypertension Prevention and Control in Nepal: An Implementation Study

TypeinterventionalSponsorKathmandu University School of Medical SciencesRan2024 to 2025Enrolled520ConditionsHypertensionArmsIntervention Group
NCT06210646 phase3completednot on this mapstarted 2022, after this paper: background citation

Citicoline in Ischemic Stroke, a Randomized Controlled Trial

TypeinterventionalSponsorKafrelsheikh UniversityRan2022 to 2024Enrolled800ConditionsIschemic StrokeArmsCiticoline 2000, citocoline 1000
NCT06337175 phase4completednot on this mapstarted 2021, after this paper: background citation

Predictors of Post-alteplase Different Subtypes of Hemorrhagic Transformation of Brain Infarction in the Middle East

TypeinterventionalSponsorKafrelsheikh UniversityRan2021 to 2024Enrolled600ConditionsIschemic Stroke, Alteplase Adverse ReactionArmsAlteplase
NCT06358313 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke, a Randomized Controlled Single-blinded Trial

TypeinterventionalSponsorKafrelsheikh UniversityRan2024 to 2026Enrolled600ConditionsIschemic StrokeArmsAtorvastatin 40mg, Rosuvastatin 20mg
NCT06360120 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke, a Randomized Controlled Single-blinded Trial

TypeinterventionalSponsorKafrelsheikh UniversityRan2024 to 2025Enrolled600ConditionsIschemic StrokeArmsAtorvastatin 40 Mg Oral Tablet, Rosuvastatin 20mg, Clopidogrel 75 Mg Oral Tablet
NCT06653946 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

the Predictors of Different ECASS-based Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients Treated With Alteplase

TypeinterventionalSponsorKafrelsheikh UniversityRan2022 to 2024Enrolled716ConditionsIschemic Stroke, Alteplase Adverse ReactionArmsAlteplase
3 · Its place in the literature

Who cites it

1,968 citing papers in PubMed, 5 syntheses or guidelines pooled it, 5,647 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Trial
  19. Review
  20. Article

1,908 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Alan D LopezSchool of Population Health, University of Queensland, Brisbane 4006, Australia. a.lopez@sph.uq.edu.au
Colin D Mathers
Majid Ezzati
Dean T Jamison
Christopher J L Murray
Harvard Global Health Institute · USHarvard University · USNational Institutes of Health · USUniversity of Queensland · AUWorld Health Organization · CH

Funding

THE GLOBAL BURDEN OF DISEASE 2000 IN AGING POPULATIONSP01AG017625 · NIA · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI MURRAY, CHRISTOPHER J.L. · 2000 to 2004
$9.4M
NIA NIH HHS P01-AG17625
6 · The paper itself

Abstract

backgroundOur aim was to calculate the global burden of disease and risk factors for 2001, to examine regional trends from 1990 to 2001, and to provide a starting point for the analysis of the Disease Control Priorities Project (DCPP).

methodsWe calculated mortality, incidence, prevalence, and disability adjusted life years (DALYs) for 136 diseases and injuries, for seven income/geographic country groups. To assess trends, we re-estimated all-cause mortality for 1990 with the same methods as for 2001. We estimated mortality and disease burden attributable to 19 risk factors.

findingsAbout 56 million people died in 2001. Of these, 10.6 million were children, 99% of whom lived in low-and-middle-income countries. More than half of child deaths in 2001 were attributable to acute respiratory infections, measles, diarrhoea, malaria, and HIV/AIDS. The ten leading diseases for global disease burden were perinatal conditions, lower respiratory infections, ischaemic heart disease, cerebrovascular disease, HIV/AIDS, diarrhoeal diseases, unipolar major depression, malaria, chronic obstructive pulmonary disease, and tuberculosis. There was a 20% reduction in global disease burden per head due to communicable, maternal, perinatal, and nutritional conditions between 1990 and 2001. Almost half the disease burden in low-and-middle-income countries is now from non-communicable diseases (disease burden per head in Sub-Saharan Africa and the low-and-middle-income countries of Europe and Central Asia increased between 1990 and 2001). Undernutrition remains the leading risk factor for health loss. An estimated 45% of global mortality and 36% of global disease burden are attributable to the joint hazardous effects of the 19 risk factors studied. Uncertainty in all-cause mortality estimates ranged from around 1% in high-income countries to 15-20% in Sub-Saharan Africa. Uncertainty was larger for mortality from specific diseases, and for incidence and prevalence of non-fatal outcomes.

interpretationDespite uncertainties about mortality and burden of disease estimates, our findings suggest that substantial gains in health have been achieved in most populations, countered by the HIV/AIDS epidemic in Sub-Saharan Africa and setbacks in adult mortality in countries of the former Soviet Union. Our results on major disease, injury, and risk factor causes of loss of health, together with information on the cost-effectiveness of interventions, can assist in accelerating progress towards better health and reducing the persistent differentials in health between poor and rich countries.

Indexed as

Cause of DeathGlobal HealthAdolescentAdultAgedAged, 80 and overAge DistributionChildChild, PreschoolFemaleHumansIncomeInfantInfant, NewbornMaleMiddle Aged

Identifiers

PMID16731270
OpenAlexW2115830594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 5 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.